Loading...
•
Jun 30
Amneal Q2 2025 Earnings Report
Amneal Pharmaceuticals reported solid growth and strong profitability in Q2 2025, leading to raised full-year guidance.
Key Takeaways
Amneal Pharmaceuticals delivered a strong second quarter in 2025, with net revenue increasing by 3% to $725 million and GAAP net income rising significantly to $22 million from $6 million in the prior year. The company also reported a substantial increase in Adjusted EBITDA and Adjusted Diluted EPS, driven by strong performance across its segments and successful debt refinancing.
Net revenue for Q2 2025 reached $725 million, marking a 3% increase compared to Q2 2024.
GAAP Net Income for the quarter was $22 million, a significant improvement from $6 million in the same period last year.
Adjusted EBITDA increased by 13% to $184 million, and Adjusted Diluted EPS rose by 56% to $0.25.
The company successfully completed a full debt refinancing, reducing interest costs and extending maturities to 2032, and subsequently raised its full-year 2025 financial guidance.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal Pharmaceuticals is raising its full-year 2025 financial guidance, reflecting confidence in continued growth and profitability.
Positive Outlook
- Net revenue guidance raised to $3.0 billion - $3.1 billion.
- Adjusted EBITDA guidance raised to $665 million - $685 million.
- Adjusted diluted EPS guidance raised to $0.70 - $0.75.
- Operating cash flow guidance raised to $275 million - $305 million.
- Operating cash flow, excluding discrete items, guidance raised to $300 million - $330 million.
Challenges Ahead
- The company cannot provide a reconciliation between non-GAAP projections and GAAP measures without unreasonable efforts due to the unpredictable nature of certain significant items.
- Future results could vary materially if underlying assumptions prove inaccurate or known/unknown risks materialize.
- Risks include competition, dependence on limited products/customers, and reliance on third-party suppliers.
- Legal, regulatory, and legislative efforts by brand competitors could deter competition from generic alternatives.
- The company's substantial indebtedness and ability to service it in the future pose a risk, along with the impact of interest rate fluctuations.
Revenue & Expenses
Visualization of income flow from segment revenue to net income